Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 691 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corticosteroid Clear all

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Conditions: Fasciitis, Plantar
Interventions: ReNu Injection, Corticosteroid Injection; Other
Lead sponsor: NuTech Medical, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Denver, Colorado • Orlando, Florida • West Des Moines, Iowa + 3 more

Conditions: COPD
Interventions: Tiotropium bromide + Olodaterol, LABA/ICS; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 42,953 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Graft Versus Host Disease
Interventions: Photopheresis, Methylprednisolone; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Verekitug (UPB-101), Placebo; Drug
Lead sponsor: Upstream Bio Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Los Angeles, California • Newport Beach, California • Roseville, California + 22 more

Conditions: Crohn's Disease
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 12
States / cities: Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more

Conditions: Osteoarthritis, Post-traumatic; Arthrosis
Interventions: methylprednisolone acetate, active comparator; Drug
Lead sponsor: New Lexington Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Canoga Park, California • San Diego, California • Hialeah, Florida + 1 more

Conditions: Adrenocortical Carcinoma
Interventions: Bevacizumab; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Liver Transplantation
Interventions: tacrolimus, mycophenolate mofetil, Prednisone; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Newport Beach, California • Denver, Colorado • Newark, Delaware + 6 more

Conditions: Renal Transplant Failure and Rejection
Interventions: Siplizumab, Rabbit anti-thymocyte globulin; Drug
Lead sponsor: Nefro Avillion Clinical Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • Tampa, Florida + 13 more

Conditions: Knee Osteoarthritis
Interventions: Ascent, Standard; Procedure
Lead sponsor: StimLabs; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Brookhaven, Georgia • Dunwoody, Georgia • Johns Creek, Georgia + 1 more

Conditions: Osteoarthritis, Knee
Interventions: FX006 32 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: El Cajon, California • La Mesa, California • Pomona, California + 5 more

Conditions: Diabetes Mellitus
Interventions: NPH, Correction Factor; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Graft Versus Host Disease
Interventions: Ruxolitinib; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Graft-versus-host Disease
Interventions: Itacitinib, Corticosteroids; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 28 Days to 18 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Duarte, California • Orange, California • Aurora, Colorado + 10 more

Conditions: Pulmonary Sarcoidosis
Interventions: Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more

Conditions: Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions: Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hemangioma
Interventions: Prednisolone (Corticosteroid), Propranolol, Placebo; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 9 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Prednisone, Topical mometasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nonneoplastic Condition
Interventions: Rituximab, Prednisone; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 23
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 20 more

Conditions: Adrenocortical Carcinoma, Adrenocortical Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

Photopheresis for the Treatment of Acute Graft Versus Host Disease

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Efficacy of Dehydrated Cell and Protein Concentrate Versus Corticosteroid

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Inpatient Diabetes on Corticosteroids

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Budesonide Inhalation Suspension for Acute Asthma in Children

Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)

Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)